Literature DB >> 20500797

Efficacy of short-duration (twice weekly) intralesional sodium stibogluconate in treatment of cutaneous Leishmaniasis in India.

R A Bumb1, R D Mehta, B C Ghiya, R Jakhar, N Prasad, P Soni, C Lezama-Davila, A R Satoskar.   

Abstract

BACKGROUND: Cutaneous leishmaniasis (CL) is caused by Leishmania major and L. tropica in the old world. Bikaner, the 'Thar Desert', situated in the north-western corner of India, is an endemic pocket for CL caused by L. tropica. Skin lesions of CL heal slowly, causing disfiguring scars if remaining untreated. Current recommended treatment for CL comprises systemic administration of sodium stibogluconate (SSG) for 2-3 weeks. Five to seven injections of SSG intralesionally have also been found to be effective.
OBJECTIVES: To determine the efficacy of a short-duration, twice-weekly intralesional SSG treatment for CL.
METHODS: Two hundred and twenty patients with CL having 298 lesions were included in the present study. They were divided into groups A and B (110 patients each). Patients were treated with five to seven intralesional injections of SSG in doses of 50 mg cm(-2) of lesion either once (group A) or twice (group B) weekly. Improvement was recorded at 6, 8, 10, 12, 16, 20 and 24 weeks and the rate of complete cure was compared.
RESULTS: Complete cure rate at 6, 8 and 10 weeks was higher (20%, 57% and 73%, respectively) in group B as compared with group A (12%, 36% and 62%, respectively). The differences in cure rates at these time points were statistically significant (P < 0.05). The complete cure rate at 24 weeks was similar in both groups (96% in group B and 92% in group A). The remaining 4% and 8% of patients in groups B and A were 'nonresponders', respectively. No major side-effects were observed in either group. In all cured cases, there were no relapses reported up to 2 years after treatment.
CONCLUSIONS: A short-duration, twice-weekly intralesional SSG treatment for CL accelerates cure and is highly effective and well tolerated.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20500797     DOI: 10.1111/j.1365-2133.2010.09865.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  12 in total

Review 1.  Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.

Authors:  Begoña Monge-Maillo; Rogelio López-Vélez
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

2.  Cutaneous leishmaniasis in a returning traveller.

Authors:  Eric Demers; David M Forrest; Gabriele E Weichert
Journal:  CMAJ       Date:  2013-03-25       Impact factor: 8.262

Review 3.  Interventions for Old World cutaneous leishmaniasis.

Authors:  Julio Heras-Mosteiro; Begoña Monge-Maillo; Mariona Pinart; Patricia Lopez Pereira; Ludovic Reveiz; Emely Garcia-Carrasco; Pedro Campuzano Cuadrado; Ana Royuela; Irene Mendez Roman; Rogelio López-Vélez
Journal:  Cochrane Database Syst Rev       Date:  2017-11-17

Review 4.  An update on pharmacotherapy for leishmaniasis.

Authors:  Shyam Sundar; Jaya Chakravarty
Journal:  Expert Opin Pharmacother       Date:  2014-10-25       Impact factor: 3.889

5.  Meglumine antimoniate is more effective than sodium stibogluconate in the treatment of cutaneous leishmaniasis.

Authors:  Yavuz Yesilova; Hacer Altın Surucu; Nurittin Ardic; Mustafa Aksoy; Abdullah Yesilova; Steve Oghumu; Abhay R Satoskar
Journal:  J Dermatolog Treat       Date:  2015-06-24       Impact factor: 3.359

Review 6.  Interventions for Old World cutaneous leishmaniasis.

Authors:  Julio Heras-Mosteiro; Begoña Monge-Maillo; Mariona Pinart; Patricia Lopez Pereira; Ludovic Reveiz; Emely Garcia-Carrasco; Pedro Campuzano Cuadrado; Ana Royuela; Irene Mendez Roman; Rogelio López-Vélez
Journal:  Cochrane Database Syst Rev       Date:  2017-12-01

7.  Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guide.

Authors:  Caspar J Hodiamont; Piet A Kager; Aldert Bart; Henry J C de Vries; Pieter P A M van Thiel; Tjalling Leenstra; Peter J de Vries; Michèle van Vugt; Martin P Grobusch; Tom van Gool
Journal:  PLoS Negl Trop Dis       Date:  2014-05-01

8.  Pediatric Cutaneous Leishmaniasis in an Endemic Region in Turkey: A Retrospective Analysis of 8786 Cases during 1998-2014.

Authors:  Mustafa Aksoy; Nebiye Doni; Hatice Uce Ozkul; Yavuz Yesilova; Nurittin Ardic; Abdullah Yesilova; Jennifer Ahn-Jarvis; Steve Oghumu; Cesar Terrazas; Abhay R Satoskar
Journal:  PLoS Negl Trop Dis       Date:  2016-07-14

Review 9.  Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review.

Authors:  Nayara Castelano Brito; Ana Rabello; Gláucia Fernandes Cota
Journal:  PLoS One       Date:  2017-09-19       Impact factor: 3.240

10.  Comparison of Efficacy of Two Different Concentrations of Intralesional Amphotericin B in the Treatment of Cutaneous Leishmaniasis; A Randomized Controlled Trial.

Authors:  Pooja Goswami; B C Ghiya; Vineet Kumar; S Rekha; R D Mehta
Journal:  Indian Dermatol Online J       Date:  2019-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.